Pancreatic beta-cell mass expands through beta-cell proliferation and neogenesis while it decreases mainly via apoptosis. The loss of balance between beta-cell death and regeneration leads to a reduction of beta-cell functional mass, thus contributing to the pathogenesis of type 2 diabetes mellitus (T2DM). The pathogenetic mechanisms causing T2DM are complex, and also include a significant reduction of the incretin effect. A better understanding of the role of incretin hormones in glucose homeostasis has led to the development of incretin-based therapies. Recently, incretin hormones have been shown to stimulate the beta-cell growth and differentiation from pancreas-derived stem/progenitor cells, as well as to exert cytoprotective, antiapopt...
Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concentratio...
Controversy exists regarding the potential regenerative influen-ces of incretin therapy on pancreati...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Pancreatic beta-cell mass expands through beta-cell proliferation and neogenesis while it decreases ...
There is a progressive deterioration inb-cell function in patients with type2 diabetes. At diagnosis...
Type 2 diabetes (T2D) is a multifaceted metabolic disorder associated with distinctive pathophysiolo...
Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogene...
Abstract An important role in the regulation of glucose homeostasis is played by incretins, which ar...
AIMS/HYPOTHESIS: Incretin-based therapies improve glycaemic control in patients with type 2 diabetes...
insulinotropic polypeptide (GIP) are incretin hormones that control the secretion of insulin, glucag...
Incretins are gut hormones secreted by cells located in the small intestine in response to ingestion...
Therapies targeting the action of incretin hormones have been under close scrutiny in recent years. ...
Type 2 diabetes (T2DM) is characterized by a deficit in pancreatic beta cell mass with increased bet...
SummaryGut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotr...
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic...
Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concentratio...
Controversy exists regarding the potential regenerative influen-ces of incretin therapy on pancreati...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Pancreatic beta-cell mass expands through beta-cell proliferation and neogenesis while it decreases ...
There is a progressive deterioration inb-cell function in patients with type2 diabetes. At diagnosis...
Type 2 diabetes (T2D) is a multifaceted metabolic disorder associated with distinctive pathophysiolo...
Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogene...
Abstract An important role in the regulation of glucose homeostasis is played by incretins, which ar...
AIMS/HYPOTHESIS: Incretin-based therapies improve glycaemic control in patients with type 2 diabetes...
insulinotropic polypeptide (GIP) are incretin hormones that control the secretion of insulin, glucag...
Incretins are gut hormones secreted by cells located in the small intestine in response to ingestion...
Therapies targeting the action of incretin hormones have been under close scrutiny in recent years. ...
Type 2 diabetes (T2DM) is characterized by a deficit in pancreatic beta cell mass with increased bet...
SummaryGut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotr...
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic...
Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concentratio...
Controversy exists regarding the potential regenerative influen-ces of incretin therapy on pancreati...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...